404 related articles for article (PubMed ID: 3511284)
1. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
Schellhammer PF; Ladaga LE; Fillion MB
J Urol; 1986 Feb; 135(2):261-4. PubMed ID: 3511283
[TBL] [Abstract][Full Text] [Related]
4. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
5. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
6. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
7. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
[TBL] [Abstract][Full Text] [Related]
8. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
10. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
[TBL] [Abstract][Full Text] [Related]
11. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
[TBL] [Abstract][Full Text] [Related]
12. Monitoring intravesical bacillus Calmette-Guerin treatment of bladder carcinoma with flow cytometry.
Staiano-Coico L; Huffman J; Wolf R; Pinsky CM; Herr HW; Whitmore WF; Oettgen HF; Darzynkiewicz Z; Melamed MR
J Urol; 1985 May; 133(5):786-8. PubMed ID: 3989917
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer immunotherapy.
Lamm DL; Thor DE; Stogdill VD; Radwin HM
J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.
Chade DC; Shariat SF; Godoy G; Savage CJ; Cronin AM; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2010 Jul; 184(1):74-80. PubMed ID: 20546806
[TBL] [Abstract][Full Text] [Related]
15. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Fair WR; Whitmore WF; Melamed MR
J Urol; 1989 Jun; 141(6):1332-6. PubMed ID: 2724430
[TBL] [Abstract][Full Text] [Related]
17. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic adenoma associated with intravesical bacillus Calmette-Guerin treatment: a report of 2 cases.
Stilmant MM; Siroky MB
J Urol; 1986 Feb; 135(2):359-61. PubMed ID: 3511292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]